Shoji, T., Takatori, E., Omi, H., Kagabu, M., Honda, T., Futagami, M., . . . Sugiyama, T. (2017). A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study). Cancer Chemother Pharmacol.
Citação norma ChicagoShoji, Tadahiro, et al. "A Phase II Study of Irinotecan and Pegylated Liposomal Doxorubicin in Platinum-resistant Recurrent Ovarian Cancer (Tohoku Gynecologic Cancer Unit 104 Study)." Cancer Chemother Pharmacol 2017.
MLA CitationShoji, Tadahiro, et al. "A Phase II Study of Irinotecan and Pegylated Liposomal Doxorubicin in Platinum-resistant Recurrent Ovarian Cancer (Tohoku Gynecologic Cancer Unit 104 Study)." Cancer Chemother Pharmacol 2017.